Seasonal variation in attacks of neuromyelitis optica spectrum disorders and multiple sclerosis: Evaluation of 794 attacks from a nationwide registry in Argentina

2021 ◽  
pp. 103466
Author(s):  
Edgar Carnero Contentti ◽  
Pablo A. Lopez ◽  
Juan Pablo Pettinicchi ◽  
Juan Criniti ◽  
Agustín Pappolla ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Seasonal Variation ◽  
Neuromyelitis Optica ◽  
Neuromyelitis Optica Spectrum Disorders ◽  
Nationwide Registry ◽  
Spectrum Disorders

scholarly journals Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders

2019 ◽  
Vol 18 (2) ◽  
pp. 185-197 ◽  
Author(s):  
Olga Ciccarelli ◽  
Jeffrey A Cohen ◽  
Stephen C Reingold ◽  
Brian G Weinshenker ◽  
Maria Pia Amato ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Spinal Cord ◽  
Neuromyelitis Optica ◽  
Neuromyelitis Optica Spectrum Disorders ◽  
Spinal Cord Involvement ◽  
Spectrum Disorders

scholarly journals Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders

2021 ◽  
pp. jnnp-2021-326904
Author(s):  
Céline Louapre ◽  
Michella Ibrahim ◽  
Elisabeth Maillart ◽  
Basma Abdi ◽  
Caroline Papeix ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Neuromyelitis Optica ◽  
Seroconversion Rate ◽  
Neuromyelitis Optica Spectrum Disorders ◽  
Linear Regression Models ◽  
Positive Serology ◽  
Humoral Immune ◽  
Antibody Positivity ◽  
Spectrum Disorders ◽  
Anti Cd20

BackgroundSARS-CoV-2 seroconversion rate after COVID-19 may be influenced by disease-modifying therapies (DMTs) in patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorders (NMO-SD).ObjectiveTo investigate the seroprevalence and the quantity of SARS-CoV-2 antibodies in a cohort of patients with MS or NMO-SD.MethodsBlood samples were collected in patients diagnosed with COVID-19 between 19 February 2020 and 26 February 2021. SARS-CoV-2 antibody positivity rates and Ig levels (anti-S IgG titre, anti-S IgA index, anti-N IgG index) were compared between DMTs groups. Multivariate logistic and linear regression models were used to estimate the influence of DMTs and other confounding variables on SARS-CoV-2 serological outcomes.Results119 patients (115 MS, 4 NMO, mean age: 43.0 years) were analysed. Overall, seroconversion rate was 80.6% within 5.0 (SD 3.4) months after infection. 20/21 (95.2%) patients without DMT and 66/77 (85.7%) patients on DMTs other than anti-CD20 had at least one SARS-CoV-2 Ig positivity, while this rate decreased to only 10/21 (47.6%) for patients on anti-CD20 (p<0.001). Being on anti-CD20 was associated with a decreased odd of positive serology (OR, 0.07 (95% CI 0.01 to 0.69), p=0.02) independently from time to COVID-19, total IgG level, age, sex and COVID-19 severity. Time between last anti-CD20 infusion and COVID-19 was longer (mean (SD), 3.7 (2.0) months) in seropositive patients compared with seronegative patients (mean (SD), 1.9 (1.5) months, p=0.04).ConclusionsSARS-CoV-2 antibody response was decreased in patients with MS or NMO-SD treated with anti-CD20 therapies. Monitoring long-term risk of reinfection and specific vaccination strategies in this population may be warranted.Trial registration numberNCT04568707.

Intrathecal IGM synthesis in multiple sclerosis and neuromyelitis optica spectrum disorders: Clinical and laboratory analysis

2017 ◽  
Vol 381 ◽  
pp. 790
Author(s):  
V. Neri ◽  
A.B. Lopes ◽  
C.O. Brandao ◽  
S. Vieira Leon ◽  
C.C. Ferreira Vasconcelos ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Neuromyelitis Optica ◽  
Laboratory Analysis ◽  
Neuromyelitis Optica Spectrum Disorders ◽  
Spectrum Disorders

Treatment options in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders

2021 ◽  
Vol 27 ◽  
Author(s):  
Paulus Rommer ◽  
Uwe K Zettl
Keyword(s):  
Multiple Sclerosis ◽  
Side Effects ◽  
Neuromyelitis Optica ◽  
Treatment Options ◽  
Spectrum Disorder ◽  
Neuromyelitis Optica Spectrum Disorder ◽  
Neuromyelitis Optica Spectrum Disorders ◽  
The Past ◽  
Drug Classes ◽  
Spectrum Disorders

: There are few diseases with as many therapeutic advances in recent years as in multiple sclerosis. Nine different drug classes with more than a dozen approved therapies are now available. Similarly, there have been unimaginable advances in understanding neuromyelitis optica (now neuromyelitis optica spectrum disorder [NMOSD]) over the past 15 years. Building on the knowledge gained, the first therapies have been approved in recent years. In this review, we aim to present all therapies approved for the treatment of MS or NMOSD. The different forms of application, different approval criteria and most important side effects will be presented. This work is intended for physicians who are interested in MS and NMOSD therapies and want to get a first overview and does not replace the respective guidelines of the regulatory authorities.

Sign in / Sign up

Export Citation Format

Share Document